PMID: 9663927Jul 15, 1998Paper

Tissue availability of insulin-like growth factor I is inversely related to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition

Journal of Hypertension
C LaviadesJ Díez

Abstract

The insulin-like growth factor I possesses biologic actions that resemble those of insulin. Tissue access of the factor depends on the distribution of the circulating bound factor between its binding protein 3 that remains within the intravascular space and its binding protein I that is able to cross the endothelium. Preliminary results have shown that tissue availability of insulin-like growth factor I is a determinant of glucose regulation in essential hypertension To investigate whether the tissue availability of circulating insulin-like growth factor I in patients with essential hypertension is related to insulin resistance and whether chronic angiotensin converting enzyme inhibition influences tissue availability of the factor and insulin resistance in these patients. We studied 29 patients with essential hypertension and 20 age-matched and sex-matched normotensive subjects. The measurements were repeated for 25 patients after 12 months of treatment with lisinopril. Tissue availability of circulating insulin-like growth factor I was assessed by analyzing its distribution between its binding proteins 3 and 1. An insulin resistance index was estimated using the homeostasis model analysis of fasting insulin-glucose interactio...Continue Reading

References

Dec 1, 1992·The Journal of Clinical Investigation·P D ZenobiE R Froesch
Oct 1, 1991·Endocrinology·S C HodgkinsonP D Gluckman
Nov 15, 1990·The New England Journal of Medicine·J D QuinA C MacCuish
Jun 1, 1990·Acta Endocrinologica·J L Van den BrandeS C van Buul-Offers
Feb 1, 1990·Metabolism: Clinical and Experimental·T PollareC Berne
Aug 1, 1989·The Journal of Clinical Endocrinology and Metabolism·M S Lewitt, R C Baxter
Oct 1, 1995·Metabolism: Clinical and Experimental·R C Baxter
Jul 1, 1995·Physiological Reviews·G M Reaven
Oct 1, 1993·Proceedings of the Society for Experimental Biology and Medicine·P D LeeD R Powell
Jul 1, 1994·American Journal of Hypertension·S Chen, B D Roufogalis
Jul 11, 1994·FEBS Letters·J FrystykH Orskov
Apr 1, 1994·Annals of Internal Medicine·C A BondyM Skarulis
Jan 1, 1995·European Journal of Clinical Pharmacology·C ThürigP Weidmann

❮ Previous
Next ❯

Citations

Jul 11, 2008·The Journal of Nutrition, Health & Aging·D SumukadasM E T McMurdo
Jan 20, 2011·Clinical Science·Elena ContiMassimo Volpe
Sep 1, 2006·Expert Review of Endocrinology & Metabolism·Rakesh Amin, David B Dunger
Mar 3, 2004·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·N Anim-NyameM J Johnson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.